Literature DB >> 6201740

Serological cross-reaction between high molecular weight proteins synthesized in blood schizonts of Plasmodium yoelii, Plasmodium chabaudi and Plasmodium falciparum.

A A Holder, R R Freeman, C I Newbold.   

Abstract

A 230 000 molecular weight (MW) Plasmodium yoelii protein, a 250 000 MW P. chabaudi protein and a 195 000 MW P. falciparum protein, identified using monoclonal antibodies, have similar characteristics, and have been implicated as protective antigens. In this study the serological relationship between these proteins was investigated by Western transfer analysis. The monoclonal antibodies specific for each of the high molecular weight proteins did not cross-react with antigens of the other two parasites, but a polyvalent mouse serum raised against the purified 230 000 MW P. yoelii protein cross-reacted with the high molecular weight proteins of P. chabaudi and P. falciparum and also with the fragments derived from these proteins. This result indicates that these proteins belong to the same class of malaria parasite antigen.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6201740     DOI: 10.1016/0166-6851(83)90096-8

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  16 in total

1.  Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene.

Authors:  J A Lyon; R H Geller; J D Haynes; J D Chulay; J L Weber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

2.  The 3' portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody.

Authors:  J M Burns; T M Daly; A B Vaidya; C A Long
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

3.  Plasmodium chabaudi antigen Pch105, Plasmodium falciparum antigen Pf155, and erythrocyte band 3 share cross-reactive epitopes.

Authors:  G Holmquist; R Udomsangpetch; K Berzins; H Wigzell; P Perlmann
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

4.  Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.

Authors:  Ute Woehlbier; Christian Epp; Christian W Kauth; Rolf Lutz; Carole A Long; Boubacar Coulibaly; Bocar Kouyaté; Myriam Arevalo-Herrera; Sócrates Herrera; Hermann Bujard
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Serum antibody immunoglobulin G of mice convalescent from Plasmodium yoelii infection inhibits growth of Plasmodium falciparum in vitro: blood stage antigens of P. falciparum involved in interspecies cross-reactive inhibition of parasite growth.

Authors:  P Ray; N Sahoo; B Singh; F A Kironde
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

6.  Studies of murine malaria antigens using monoclonal antibodies. Production, selection, and characterization of antibodies.

Authors:  G Holmquist; P Borwell; A R Cattan; H Wigzell
Journal:  Z Parasitenkd       Date:  1986

7.  T-cell recognition of a cross-reactive antigen(s) in erythrocyte stages of Plasmodium falciparum and Plasmodium yoelii: inhibition of parasitemia by this antigen(s).

Authors:  B Lucas; A Engels; D Camus; A Haque
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

8.  Malaria specific human T cell clones: crossreactivity with various plasmodia species.

Authors:  P Simitsek; C Chizzolini; L Perrin
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

9.  Immunoelectrophoretic analysis of erythrocytic stages of Plasmodium yoelii and P. chabaudi.

Authors:  J Carlsson; K Berzins; P Perlmann
Journal:  Z Parasitenkd       Date:  1984

10.  Vaccination with a purified blood-stage malaria antigen in mice: correlation of protection with T cell mediated immunity.

Authors:  J H Playfair; J B De Souza; R R Freeman; A A Holder
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.